VivoSeq
Other

Irritation

0

Pipeline Programs↗

2

Active Trials↗

16

Companies Involved↗

Irritation is an early-stage landscape with 0 programs across 16 companies. The most active players are Pfizer, LEO Pharma, GSK.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

0 programs

PreclinicalLEO Pharma logo

LEO Pharma

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalN

Noven Pharmaceuticals, Inc.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

55

clinical trials

Completed48 · 87%
Unknown status3 · 5%
Not yet recruiting1 · 2%
Withdrawn1 · 2%
Terminated1 · 2%
Recruiting1 · 2%

Clinical Trials

Trial Activity

55 trials

Assessment of Skin Irritation and Sensitization of SILURCLOUD Fibrous Collagen Matrix
Recruiting·SSerenaGroup, Inc.·N/A·NCT07473661·20 enrolled
A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects
Not yet recruiting·CCorium Innovations, Inc.·Phase 1·NCT07452692·230 enrolled
Cumulative Irritation Test
Completed·Pfizer logoPfizer·Phase 1·NCT00781664·44 enrolled
A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment
Completed·CCastle Creek Pharmaceuticals, LLC·Phase 1·NCT03472534·46 enrolled
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
Completed·BBausch Health Americas, Inc.·Phase 4·NCT01313728·26 enrolled
Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100
Completed·LEO Pharma logoLEO Pharma·Phase 1·NCT01935869·224 enrolled
Study to Investigate the Irritation Potential of GSK1940029 Gel
Completed·GSK logoGSK·Phase 1·NCT01984801·54 enrolled
Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System
Completed·TTeikoku Pharma USA, Inc.·Phase 2·NCT00916383·49 enrolled
Irritation and Sensitization Study of d-Amphetamine Transdermal System
Completed·NNoven Therapeutics·Phase 1·NCT04094025·229 enrolled
Gingival Irritation Due to Bleaching Tray Design in an At-home Bleaching Treatment
Completed·UUniversity of Santiago de Compostela·Phase 1·NCT06371664·72 enrolled
Evaluation of Adhesion Quality and Irritation of an Alternate Second Generation Estradiol Transdermal System
Completed·Mylan Pharmaceuticals Inc logoMylan Pharmaceuticals Inc·Phase 1·NCT00650442·39 enrolled
Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design
Completed·MMoberg Pharma AB·Phase 1·NCT06369675·45 enrolled
Cumulative Skin Irritation Potential of a New 25 mg Nicotine Patch
Completed·MMcNeil AB·Phase 1·NCT00967174·42 enrolled
Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion
Completed·—·Phase 1·NCT02061813·40 enrolled
Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects
Completed·LEO Pharma logoLEO Pharma·Phase 1·NCT02379793·33 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)